Background— It is pathophysiologically conceivable that genetic variations in coagulation
and fibrinolytic proteins are associated with the risk of myocardial infarction. Methods and …

Plaque disruption with superimposed thrombosis is the main cause of acute coronary events
such as acute myocardial infarction and unstable angina. Among other factors, tissue factor …

Background Despite the use of aspirin, there is still a risk of ischaemic events after
percutaneous coronary intervention (PCI). We aimed to find out whether, in addition to aspirin, …

Background: Web-based interventions can improve single cardiovascular risk factors in
adult populations. In view of global aging and the associated increasing burden of …

Context Despite many therapeutic advances, mortality in patients with acute ST-segment
elevation myocardial infarction (STEMI) remains high. The role of additional antithrombotic …

Background— We studied the benefits and risks of adding clopidogrel to different doses of
aspirin in the treatment of patients with acute coronary syndrome (ACS). Methods and Results…

Background Previous trials have shown that the use of statins to lower cholesterol reduces
the risk of cardiovascular events among persons without cardiovascular disease. Those trials …

Background Antihypertensive therapy reduces the risk of cardiovascular events among high-risk
persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its …

Background Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol
increase the risk of cardiovascular disease. Lowering both should reduce the risk of …

Background— The novel anticoagulant fondaparinux proved to be effective and safe in the
postoperative prevention of venous thrombosis. Current phase III trials with this synthetic …